Virtus Advisers LLC Decreases Stake in Amicus Therapeutics, Inc. $FOLD

Virtus Advisers LLC trimmed its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 75.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,523 shares of the biopharmaceutical company’s stock after selling 14,129 shares during the period. Virtus Advisers LLC’s holdings in Amicus Therapeutics were worth $26,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Strs Ohio purchased a new position in Amicus Therapeutics in the first quarter worth approximately $30,000. PNC Financial Services Group Inc. raised its holdings in shares of Amicus Therapeutics by 211.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 3,497 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Amicus Therapeutics during the 1st quarter worth $53,000. CWM LLC lifted its position in shares of Amicus Therapeutics by 395.9% during the 2nd quarter. CWM LLC now owns 9,397 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 7,502 shares during the last quarter. Finally, Inceptionr LLC acquired a new position in shares of Amicus Therapeutics during the second quarter worth $61,000.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on FOLD shares. Needham & Company LLC upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Thursday, September 18th. The Goldman Sachs Group increased their price objective on Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Wall Street Zen raised Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Amicus Therapeutics in a research note on Tuesday, November 25th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Amicus Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Amicus Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $16.57.

Insider Buying and Selling at Amicus Therapeutics

In related news, insider David Michael Clark sold 25,643 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $10.10, for a total transaction of $258,994.30. Following the completion of the sale, the insider owned 296,975 shares in the company, valued at $2,999,447.50. This represents a 7.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jeff Castelli sold 76,158 shares of the firm’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $10.16, for a total transaction of $773,765.28. Following the transaction, the insider directly owned 439,318 shares in the company, valued at $4,463,470.88. The trade was a 14.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 201,652 shares of company stock worth $2,019,288 in the last 90 days. Company insiders own 2.20% of the company’s stock.

Amicus Therapeutics Stock Down 1.3%

Amicus Therapeutics stock opened at $9.80 on Tuesday. The company has a market capitalization of $3.02 billion, a P/E ratio of -81.66 and a beta of 0.66. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21. Amicus Therapeutics, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $10.57. The stock has a 50-day simple moving average of $8.82 and a 200-day simple moving average of $7.43.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.12 by $0.05. Amicus Therapeutics had a negative return on equity of 5.07% and a negative net margin of 6.67%.The company had revenue of $169.06 million for the quarter, compared to analyst estimates of $165.24 million. During the same quarter in the previous year, the company posted $0.10 earnings per share. The firm’s revenue was up 19.5% compared to the same quarter last year. Amicus Therapeutics has set its FY 2025 guidance at EPS. Equities research analysts expect that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current year.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.